VRCA

Verrica Pharmaceuticals' stock price increased by 127.64% over the past six months. The company reported its Fourth Quarter and Full Year 2025 financial results, highlighting record revenue growth. YCANTH was launched in Japan by Torii Pharmaceutical. Zacks upgraded Verrica Pharmaceuticals to a "Strong Buy" rating. The company announced the acceptance of a late-breaking abstract highlighting the potential abscopal effect of VP-315. Verrica announced an upcoming presentation of Phase 2 data for VP-315, which led to a 12.58% increase in the stock price. Verrica is scheduled to report its first-quarter 2026 financial results and provide a corporate update on May 12, 2026.